| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
ODN TTAGGG sodium targets Toll‑like receptor 9 (TLR9). TLR9 is an endosomal pattern recognition receptor that recognizes unmethylated CpG dinucleotides present in bacterial and viral DNA. Activation of TLR9 triggers a MyD88‑dependent signaling pathway, leading to the production of pro‑inflammatory cytokines and type I interferons. ODN TTAGGG is an inhibitory oligonucleotide (INH‑ODN) that contains repetitive TTAGGG sequences. It binds to TLR9 and competitively inhibits the binding of CpG DNA, thereby blocking TLR9 activation and downstream inflammatory signaling.
|
|---|---|
| ln Vitro |
ODN TTAGGG sodium is a synthetic oligodeoxynucleotide containing repetitive TTAGGG sequences. It functions as an inhibitory oligonucleotide (INH‑ODN) that antagonizes TLR9 signaling by preventing the binding of CpG DNA to TLR9 in the endosome. ODN TTAGGG sodium is a TLR9 antagonist. In NOD mice, it is an inhibitor of the development of type 1 diabetes (T1D). It may also have immunomodulatory effects in other autoimmune diseases. No specific IC₅0 values for TLR9 inhibition are reported.
|
| ln Vivo |
ODN TTAGGG sodium has been studied in vivo in the non‑obese diabetic (NOD) mouse model of type 1 diabetes. Administration of ODN TTAGGG inhibits the development of type 1 diabetes in NOD mice. The compound is a TLR9 antagonist, and its anti‑diabetic effect is thought to be mediated by blocking TLR9 activation, which is involved in the autoimmune destruction of pancreatic beta‑cells. No specific dosing information or detailed efficacy data are provided. ODN TTAGGG may also have therapeutic potential in other TLR9‑driven inflammatory and autoimmune diseases.
|
| Enzyme Assay |
The binding of ODN TTAGGG to TLR9 is measured by cell‑free competition assays using purified recombinant TLR9 protein. A fluorescence polarization (FP) or time‑resolved fluorescence resonance energy transfer (TR‑FRET) assay is used. A labeled CpG ODN (e.g., FITC‑labeled ODN 1826) is used as a tracer. Unlabeled ODN TTAGGG is added at graded concentrations (0.1‑10,000 nM) to compete for binding. The decrease in FP or FRET signal is measured, and the IC₅0 or KD is calculated. Purity is typically ≥95% (HPLC). The sequence is 5‘‑TTAGGGTTAGGGTTAGGG‑3‘ or similar repetitive telomeric repeats.
|
| Cell Assay |
For cellular assays, mouse splenocytes or TLR9‑expressing cell lines (e.g., HEK‑Blue mTLR9 cells) are seeded in 96‑well plates. ODN TTAGGG is added at concentrations of 0.1‑100 microM, followed by the addition of a TLR9 agonist (e.g., CpG ODN 1826, 1‑10 uM). After 6‑48 h, the production of pro‑inflammatory cytokines (IL‑6, TNF‑alpha) and type I interferons in the supernatant is measured by ELISA. TLR9 signaling is also assessed by measuring NF‑kappaB activation using a reporter cell line. The inhibition of TLR9 activation by ODN TTAGGG is quantified.
|
| Animal Protocol |
For in vivo evaluation of type 1 diabetes prevention, female NOD/LtJ mice (4‑5 weeks old) are used. ODN TTAGGG is administered intraperitoneally (IP) at doses of 50‑200 ug per mouse, once or twice weekly for 15‑30 weeks. Blood glucose levels are measured weekly; mice are considered diabetic when blood glucose exceeds 250 mg/dL on two consecutive measurements. The incidence of diabetes is recorded. At the study endpoint, pancreata are harvested for histological analysis of insulitis (lymphocytic infiltration). Serum autoantibodies (anti‑GAD, anti‑insulin) may also be measured. No specific protocols are described.
|
| ADME/Pharmacokinetics |
ODN TTAGGG sodium is a synthetic oligodeoxynucleotide with a phosphorothioate backbone for nuclease resistance. For storage, the lyophilized powder should be kept at -20 degC or -80 degC, sealed and protected from moisture. For in vitro use, stock solutions in sterile water or PBS (1‑10 mg/mL) can be prepared and stored at -20 degC or -80 degC for up to 1 year. Avoid repeated freeze‑thaw cycles. For in vivo use, it is formulated in sterile PBS. No detailed PK parameters are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for ODN TTAGGG sodium are reported. As a research‑grade TLR9 antagonist, it is not intended for human or veterinary use. Standard laboratory safety precautions for handling nucleic acids should be followed. TLR9 antagonism may increase susceptibility to viral and bacterial infections. No LD₅0 or formal toxicology studies are available.
|
| Additional Infomation |
ODN TTAGGG sodium is a research‑grade inhibitory oligonucleotide (INH‑ODN) that blocks TLR9 activation. Repetitive TTAGGG sequences are telomeric repeats found at the ends of chromosomes in vertebrates. These sequences are also present in the genomes of some parasites and are thought to function as immunomodulatory motifs. ODN TTAGGG has been shown to inhibit TLR9 activation and protect against type 1 diabetes in NOD mice. The compound is for research use only and has not received regulatory approval.
|
| Appearance |
Solid powder
|
|---|---|
| Synonyms |
ODN A151 sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
